Abstract
Efficient Data Analysis (EDA) was designed specifically to address quality control (QC) decisions with respect to the CI-measured APSD from an OIP. The general goal of QC testing is to confirm that the batch in question is of suitable quality. In the case of EDA, this testing is intended to confirm that the OIP in question generates an aerosol with expected particle size characteristics to deliver drug to the human respiratory tract. Note that this process necessarily takes the form of sampling a relatively small number of units, measuring properties of the aerosols generated by these samples, and making a decision concerning the quality of the sampled batch. This practice leads to three primary considerations:
-
1.
The properties measured should be relevant to detecting significant abnormalities from the expected APSD.
-
2.
The measurements should possess sufficient precision and accuracy over the range of interest.
-
3.
The decision process based on the measurements should reliably make correct inference about the quality of the batch by appropriately minimizing and balancing the risk of decision errors, i.e., judging a batch suitable when it is not suitable and conversely judging a batch unsuitable when it is suitable.
This chapter will briefly introduce the latter two considerations, but will primarily focus on the first. A detailed discussion of the evaluation of measurements and the decision-making process is the topic of Chap. 8.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Newman SP, Chan H-K (2008) In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med 21(1):1–8
Heyder J, Svartengren MU (2002) Basic principles of particle behavior in the human respiratory tract. In: Bisgaard H, O’Callaghan C, Smaldone GC (eds) Drug delivery to the lung. Marcel Dekker, New York
Dolovich M (2002) Airway delivery devices and airways/lung deposition. In: Schleimer R, O’Byrne PM, Szefler S, Brattsand R (eds) Inhaled steroids in asthma. Marcel Dekker, New York, NY, pp 169–212
Usmani OS, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ (2003) Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 95:2106–2112
Usmani OS, Biddiscombe MF, Barnes PJ (2005) Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med 172(12):1497–1504
Zanen P, Go LT, Lammers JWJ (1994) The optimal particle size for beta-adrenergic aerosols in mild asthmatics. Int J Pharm 107:211–217
Zanen P, Go LT, Lammers JWJ (1995) The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharm 114:111–115
Zanen P, Go LT, Lammers JWJ (1996) Optimal particle size for beta-agonist and anticholinergic aerosols in patients with severe airflow limitation. Thorax 51:977–980
Newman SP (1998) How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 11(S1):S97–S104
Newman SP, Wilding IR, Hirst PH (2000) Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 208:49–60
Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S (2009) Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs). AAPS PharmSciTech 10(4):1276–1285
Wheeler DJ (2006) EMP (evaluating the measurement process) III: using imperfect data. SPC, Knoxville, TN
AIAG (Automotive Industry Action Group) (2010) Measurement system analysis, reference manual, 4th edn. AIAG, Southfield, MI, USA, ISBN#: 978-1-60-534211-5
Bower KM, Touchton ME (2001) Evaluating the usefulness of data by gage repeatability and reproducibility. Asia Pacific Process Engineer. http://www.minitab.com/en-US/training/articles/default.aspx. Accessed 22 July 2012
Tougas TP (2006) Considerations of the role of end product testing in assuring the quality of pharmaceutical products. Process Anal Technol 3:13–17
Summers DCS (1997) Quality. Prentice Hall, Upper Saddle River, NJ
Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med 18(4):439–451
Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D (2003) Next generation pharmaceutical impactor. Part 1: Design. J Aerosol Med 16:283–299
Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols from medical inhalers; their uses and limitations. J Aerosol Med 16:341–376
O’Shaughnessy PT, Raabe OG (2003) A comparison of cascade impactor data reduction methods. Aerosol Sci Technol 37(2):187–200
US Food and Drug Administration (FDA) (1998) CDER. Draft guidance for industry metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and controls documentation, Rockville, MD, USA. http://www.fda.gov/cder/guidance/2180dft.pdf. Accessed 15 July 2012
European Medicines Agency (EMA) (2006) Guideline on the pharmaceutical quality of inhalation and nasal products. London, UK, EMEA/CHMP/QWP/49313/2005 Final. http://www.ema.europa.eu/pdfs/human/qwp/4931305en.pdf. Accessed 20 Jan 2012
Health Canada (2006) Guidance for industry: pharmaceutical quality of inhalation and nasal products. File Number file number: 06-106624-547. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/inhalationnas-eng.pdf. Accessed 20 Jan 2012
Hinds WC (1999) Aerosol technology: properties, behavior, and measurement of airborne particles, 2nd edn. John Wiley & Sons, New York
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tougas, T.P., Mitchell, J.P. (2013). Theoretical Basis for the EDA Concept. In: Tougas, T., Mitchell, J., Lyapustina, S. (eds) Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-6296-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6296-5_7
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-6295-8
Online ISBN: 978-1-4614-6296-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)